The basal-like type lacking hormone receptors and overexpressing HER2 is often considered triple-negative breast cancer, which can only be treated with chemotherapy, and is more common in patients with BRCA1 mutations or African ancestry [24, 25]. This evidence concerns the gene NR4A1 and triple-negative breast carcinoma.